SEC Comment Letter 0000000000-23-013049 to Perspective Therapeutics, Inc. (CATX) (CIK 0000728387) (CATX)
Perspective Therapeutics, Inc. (CATX) (CIK 0000728387)
Date: Nov. 30, 2023 · CIK: 0000728387 · Accession: 0000000000-23-013049
AI Filing Summary & Sentiment
File numbers found in text: 333-275638
Letter
United States securities and exchange commission logo November 30, 2023 Johan (Thijs) Spoor Chief Executive Officer Perspective Therapeutics, Inc. 2401 Elliott Avenue, Suite 320 Seattle, WA 98121 Re:Perspective Therapeutics, Inc. Registration Statement on Form S-3 Filed November 17, 2023 File No. 333-275638 Dear Johan (Thijs) Spoor: We have conducted a limited review of your registration statement and have the following comments. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Registration Statement on Form S-3 General 1.It appears that the aggregate market value of the shares of your common stock held by non-affiliates during the 60 days prior to November 17, 2023, did not appear to exceed the $75 million threshold that General Instruction I.B.1 of Form S-3 specifies. Please provide us with your analysis demonstrating your ability to use Form S-3 pursuant to General Instruction I.B.1. Alternatively, if you are relying on General Instruction I.B.6 for S- 3 eligibility, please include the information required pursuant to Instruction 7 to General Instruction I.B.6. 2.In your Form 10-Q filed for the quarter ended September 30, 2023, you note that the results of operations for Viewpoint Molecular Targeting, Inc. following the acquisition that closed February 3, 2023, disclosed on Form 8-K as amended on April 21, 2023, are only reflected post-acquisition. Please advise what consideration was given to providing a pro forma income statement for the nine months ended September 30, 2023, which would
FirstName LastNameJohan (Thijs) Spoor Comapany NamePerspective Therapeutics, Inc. November 30, 2023 Page 2 FirstName LastName Johan (Thijs) Spoor Perspective Therapeutics, Inc. November 30, 2023 Page 2 include the pre-acquisition period of January 1, 2023 to February 3, 2023, under Article 11 of Regulation S-X. Additionally, please file as an exhibit a consent from Weinberg & Company, P.A., as was included with the Form 8-K. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Benjamin Richie at 202-551-7857 or Margaret Schwartz at 202-551-7153 with any other questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Andrew Strong
Show Raw Text
United States securities and exchange commission logo
November 30, 2023
Johan (Thijs) Spoor
Chief Executive Officer
Perspective Therapeutics, Inc.
2401 Elliott Avenue, Suite 320
Seattle, WA 98121
Re:Perspective Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 17, 2023
File No. 333-275638
Dear Johan (Thijs) Spoor:
We have conducted a limited review of your registration statement and have the
following comments.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Registration Statement on Form S-3
General
1.It appears that the aggregate market value of the shares of your common stock held by
non-affiliates during the 60 days prior to November 17, 2023, did not appear to exceed the
$75 million threshold that General Instruction I.B.1 of Form S-3 specifies. Please provide
us with your analysis demonstrating your ability to use Form S-3 pursuant to General
Instruction I.B.1. Alternatively, if you are relying on General Instruction I.B.6 for S-
3 eligibility, please include the information required pursuant to Instruction 7 to General
Instruction I.B.6.
2.In your Form 10-Q filed for the quarter ended September 30, 2023, you note that the
results of operations for Viewpoint Molecular Targeting, Inc. following the acquisition
that closed February 3, 2023, disclosed on Form 8-K as amended on April 21, 2023, are
only reflected post-acquisition. Please advise what consideration was given to providing a
pro forma income statement for the nine months ended September 30, 2023, which would
FirstName LastNameJohan (Thijs) Spoor
Comapany NamePerspective Therapeutics, Inc.
November 30, 2023 Page 2
FirstName LastName
Johan (Thijs) Spoor
Perspective Therapeutics, Inc.
November 30, 2023
Page 2
include the pre-acquisition period of January 1, 2023 to February 3, 2023, under Article
11 of Regulation S-X. Additionally, please file as an exhibit a consent from Weinberg
& Company, P.A., as was included with the Form 8-K.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Benjamin Richie at 202-551-7857 or Margaret Schwartz at 202-551-7153
with any other questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Andrew Strong